SOTIO is a biotechnology company developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit. SOTIO is owned by the PPF Group, one of the largest investment groups in Central and Eastern Europe.

SOTIO uses its own active cellular immunotherapy platform (DCVAC products), based on dendritic cells for the treatment of cancer and conducting multiple
Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products for personalized treatment of prostate, ovarian and lung cancer. SOTIO also initiated SC103, a first-in-human Phase I clinical trial
with SO-C101 program developed
by Cytune Pharma.

SOTIO aims to become a mid-sized specialty pharma company that develops and commercializes innovative cancer therapeutics. We are building a diversified pipeline through internal development as well as strategic partnering. Our current licensing focus are innovative oncology therapies in advanced preclinical or clinical stage.